Wockhardt Limited (WOCKPHARMA.BO)

INR 1450.6

(0.36%)

Market Cap (In INR)

235.67 Billion

Revenue (In INR)

27.89 Billion

Net Income (In INR)

-4.63 Billion

Avg. Volume

54.78 Thousand

Currency
INR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
378.65-1536.4
PE
-
EPS
-
Beta Value
1.51
ISIN
INE049B01025
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Habil Fakhruddin Khorakiwala
Employee Count
-
Website
https://www.wockhardt.com
Ipo Date
2000-04-18
Details
Wockhardt Limited, a pharmaceutical and biotech company, manufactures and markets pharmaceuticals, medicinal, and chemical products in India, the United States, the United Kingdom, Switzerland, Ireland, Mexico, Russia, and internationally. It develops various molecules primarily in the areas of infectious diseases, such as WCK 5222, WCK 4282, WCK 4873, WCK 771 and WCK 2349, and WCK 6777 molecules; and active pharmaceutical ingredients. The company's biopharmaceutical products include Glaritus, a long-acting biosimilar glargine; Wosulin, a recombinant human insulin; Wepox, an r-DNA erythropoietin; human insulin; and Biovac-B, a hepatitis B vaccine. Its pipeline also includes long-acting insulin analogues, concentrated insulins, GLP1 analogues, haemopoietins, biobetters and novel products, and delivery devices. It also provides contract manufacturing services. The company was founded in 1967 and is headquartered in Mumbai, India.